Obesity is regarded as a major public
health concern, owing to the multifaceted factors involved in metabolic
complications rooted in multifactorial causes (e.g., environmental toxicity or
genetic abnormality), as well as the unmet landscape of the health-care system
in search of therapeutic or prevention methods. Evidence that supports Omics as
a strategic tool of systemic biology is being used to define the wiring of the
molecular circuit in metabolic malfunctions, as well as the evaluation of
metabolic modulators such as synthetic drugs, stem cell replacement, and
natural secondary metabolites derived from various sources. The link between
the nutritional environment and cellular/genetic processes is referred to as
nutritional genomics or Nutrigenomics. Its goal is to figure out how nutrition
affects a person's genes and health. Nutrigenomics strives to give a genetic
understanding of how common food ingredients (i.e., nutrition) modify the
expression or structure of an individual's genetic makeup, hence affecting the
balance of health and sickness. Furthermore, enhancing detection capabilities
from patient clinical samples and monitoring illness progression in reserve
populations, who may be at a higher risk of disease susceptibility due to
numerous micro- and macro-environmental variables, remains a preventative
thread in public health informatics. By utilising the omics platform, which
includes epigenetics, metabolomics, nutrigenomics, transcriptomics,
pharmacogenomics, and genomics, molecular-based detection systems can forecast
evolving disease in terms of key molecule modifications that may contribute to
disease pathogenesis and reflect heredity, such as quantitative trait loci,
polymorphism, and epigenetic modification. Furthermore, a customised or personalised
approach to treating metabolic disease could be applied by building a person's
health algorithm in conjunction with a molecular chain-based surveillance and
prevention system. To encourage effective biomarker discoveries in the field of
molecular therapy and early detection target molecules in obesity, early
diagnostic tools as a potential strategy has inspired us in clinical validation
and assessment to improve prevention/treatment outcomes for a better
translation medicine process. In this short review, we aim to better understand
the interaction and connectivity between risks and metabolic disorders like
obesity by utilising the molecular drive platform that OMICS technologies are
worthy of developing a clinical assessment with regard to diagnosing,
predicting, and treating metabolic disease chains (i.e., initiation, progress,
and determination) and defining causative molecule-based wiring on host defence
machinery after exposure to various unknown unknown unknown unknown unknown
unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
unknown unknown unknown unknown unknown unknown unknown unknown Nutrigenomics,
as a crucial strategical method to detecting genetic variation or disclosing
faults of the host defence system in metabolic disorders, can be used not only
to assess one's risk for obesity, but also to treat obesity through the
creation of individualised diet regimens.
Author(s) Details:
S. Bartley
Department of Public Health, Division of Environmental Health Science, New
York Medical College, Valhalla NY 10595, USA.
H. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501,
Jinju-City, Gyeongsangnamdo, 660-701, Korea.
D. E. Heck,
Department of Public Health, Division of Environmental Health Science, New York
Medical College, Valhalla NY 10595, USA.
J. H. Cho,
College of Veterinary Medicine, Gyeongsang National University, Jiju Daero 501,
Jinju-City, Gyeongsangnamdo, 660-701, Korea.
H. D. Kim,
Department of Public Health, Division of Environmental Health Science, New York
Medical College, Valhalla NY 10595, USA.
Please see the link here: https://stm.bookpi.org/ETDHR-V4/article/view/6049
